Establishment and maintenance of Kaposi's sarcoma-associated herpesvirus latency in B cells

被引:53
作者
Chen, L [1 ]
Lagunoff, M [1 ]
机构
[1] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA
关键词
D O I
10.1128/JVI.79.22.14383-14391.2005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Kaposi's sarcoma (KS)-associated herpesvirus (KSHV) is the infectious cause of Kaposi's sarcoma and is also associated with two B-cell lymphoproliferative diseases, primary effusion lymphoma and the plasmablastic form of multicentric Castleman's disease. KSHV is also found in the B-cell fraction of peripheral blood mononucleocytes of some KS patients. Despite in vivo infection of B cells and the ability of KSHV to infect many cell types in culture, to date B cells in culture have been resistant to KSHV infection. However, as shown here, the lack of infection is not due to the inability of B cells to support latent KSHV infection. When KSHV DNA is introduced into B cells, the virus is maintained as an episome and can establish and maintain latency over the course of months. As in all primary effusion lymphoma cell lines, there is a low level of spontaneous lytic replication in latently infected BJAB cells. Importantly, viral gene expression is similar to that of primary effusion lymphoma cell lines. Furthermore, the virus can be reactivated to higher levels with specific stimuli and transmitted to other cells, indicating that this is a productive infection. Thus B cells in culture are capable of establishing, maintaining, and reactivating from latency. These studies provide a controlled system to analyze how KSHV alters B cells during KSHV latency and reactivation.
引用
收藏
页码:14383 / 14391
页数:9
相关论文
共 56 条
[1]   Integrin α3β1 (CD 49c/29) is a cellular receptor for Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) entry into the target cells [J].
Akula, SM ;
Pramod, NP ;
Wang, FZ ;
Chandran, B .
CELL, 2002, 108 (03) :407-419
[2]   Human herpesvirus 8 interaction with target cells involves heparan sulfate [J].
Akula, SM ;
Wang, FZ ;
Vieira, J ;
Chandran, B .
VIROLOGY, 2001, 282 (02) :245-255
[3]   HERPES-LIKE SEQUENCES IN HIV-INFECTED AND UNINFECTED KAPOSIS-SARCOMA PATIENTS [J].
AMBROZIAK, JA ;
BLACKBOURN, DJ ;
HERNDIER, BG ;
GLOGAU, RG ;
GULLETT, JH ;
MCDONALD, AR ;
LENNETTE, ET ;
LEVY, JA .
SCIENCE, 1995, 268 (5210) :582-583
[4]  
Ansari MQ, 1996, AM J CLIN PATHOL, V105, P221
[5]   Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus [J].
Arvanitakis, L ;
Mesri, EA ;
Nador, RG ;
Said, JW ;
Asch, AS ;
Knowles, DM ;
Cesarman, E .
BLOOD, 1996, 88 (07) :2648-2654
[6]   Host range of Kaposi's sarcoma-associated herpesvirus in cultured cells [J].
Bechtel, JT ;
Liang, YY ;
Hvidding, J ;
Ganem, D .
JOURNAL OF VIROLOGY, 2003, 77 (11) :6474-6481
[7]   The restricted cellular host range of human herpesvirus 8 [J].
Blackbourn, DJ ;
Lennette, E ;
Klencke, B ;
Moses, A ;
Chandran, B ;
Weinstein, M ;
Glogau, RG ;
Witte, MH ;
Way, DL ;
Kutzkey, T ;
Herndier, B ;
Levy, JA .
AIDS, 2000, 14 (09) :1123-1133
[8]   Establishing a KSHV+ cell line (BCP-1) from peripheral blood and characterizing its growth in Nod/SCID mice [J].
Boshoff, C ;
Gao, SJ ;
Healy, LE ;
Matthews, S ;
Thomas, AJ ;
Coignet, L ;
Warnke, RA ;
Strauchen, JA ;
Matutes, E ;
Kamel, OW ;
Moore, PS ;
Weiss, RA ;
Chang, Y .
BLOOD, 1998, 91 (05) :1671-1679
[9]   A new primary effusion lymphoma-derived cell line yields a highly infectious Kaposi's sarcoma herpesvirus-containing supernatant [J].
Cannon, JS ;
Ciufo, D ;
Hawkins, AL ;
Griffin, CA ;
Borowitz, MJ ;
Hayward, GS ;
Ambinder, RF .
JOURNAL OF VIROLOGY, 2000, 74 (21) :10187-10193
[10]   The tyrosine kinase receptor Met and its ligand HGF are co-expressed and functionally active in HHV-8 positive primary effusion lymphoma [J].
Capello, D ;
Gaidano, G ;
Gallicchio, M ;
Gloghini, A ;
Medico, E ;
Vivenza, D ;
Buonaiuto, D ;
Fassone, L ;
Avanzi, GC ;
Saglio, G ;
Prat, M ;
Carbone, A .
LEUKEMIA, 2000, 14 (02) :285-291